Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 13/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930340 | 0.91 | CASR (1.00) | CASRSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL312818 | 0.91 | CASR (1.00) | CASRSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL311858 | 0.91 | CASR (1.00) | CASRSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL3921348 | 0.87 | CASR (0.80) | CASRSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL3926738 | 0.87 | CASR (0.79) | CASRSMN1; SMN2KMT2A | |
| SCHEMBL3932069 | 0.85 | CASR (0.74) | CASRSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3926029 | 0.83 | CASR (0.74) | CASRSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3920473 | 0.83 | CASR (0.74) | CASRSMN1; SMN2KMT2AMEN1AKR1C3 | |
| SCHEMBL3922401 | 0.82 | CASR (0.76) | CASRSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3923082 | 0.82 | CASR (1.00) | CASRKMT2AAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027052-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASE | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2008-01-31 | — | — | US | claimed |
| US-20080027052-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASE | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027052-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASE | PKD2, PKD1, REN | CASR 14/4885SMN1; SMN2 4423/4885KMT2A 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.